SG11201907948TA - Formulations comprising pd-1 binding proteins and methods of making thereof - Google Patents

Formulations comprising pd-1 binding proteins and methods of making thereof

Info

Publication number
SG11201907948TA
SG11201907948TA SG11201907948TA SG11201907948TA SG11201907948TA SG 11201907948T A SG11201907948T A SG 11201907948TA SG 11201907948T A SG11201907948T A SG 11201907948TA SG 11201907948T A SG11201907948T A SG 11201907948TA SG 11201907948T A SG11201907948T A SG 11201907948TA
Authority
SG
Singapore
Prior art keywords
international
formulations
pct
making
methods
Prior art date
Application number
SG11201907948TA
Other languages
English (en)
Inventor
Xiao-Ping Dai
Douglas Banks
Willard R Foss
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63678296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201907948T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SG11201907948TA publication Critical patent/SG11201907948TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11201907948TA 2017-03-29 2018-03-28 Formulations comprising pd-1 binding proteins and methods of making thereof SG11201907948TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478524P 2017-03-29 2017-03-29
PCT/US2018/024787 WO2018183459A1 (fr) 2017-03-29 2018-03-28 Formulations comprenant des protéines se liant à pd-1 et leurs procédés de préparation

Publications (1)

Publication Number Publication Date
SG11201907948TA true SG11201907948TA (en) 2019-09-27

Family

ID=63678296

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907948TA SG11201907948TA (en) 2017-03-29 2018-03-28 Formulations comprising pd-1 binding proteins and methods of making thereof

Country Status (16)

Country Link
US (1) US20180289802A1 (fr)
EP (1) EP3601338A4 (fr)
JP (1) JP2020512359A (fr)
KR (1) KR20190141658A (fr)
CN (1) CN110678482A (fr)
AU (1) AU2018246252A1 (fr)
BR (1) BR112019018996A2 (fr)
CA (1) CA3055984A1 (fr)
CL (1) CL2019002605A1 (fr)
CO (1) CO2019010230A2 (fr)
EA (1) EA201991912A1 (fr)
EC (1) ECSP19076344A (fr)
IL (1) IL268884A (fr)
MX (1) MX2019010999A (fr)
SG (1) SG11201907948TA (fr)
WO (1) WO2018183459A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
EA201890790A1 (ru) 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
WO2018053405A1 (fr) 2016-09-19 2018-03-22 Celgene Corporation Procédés de traitement de troubles immunitaires à l'aide de protéines de liaison à pd-1
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
EP4008345A1 (fr) * 2020-12-03 2022-06-08 Hexal AG Nouvelles formulations pour des anticorps
AR126614A1 (es) * 2021-07-29 2023-10-25 Shanghai Junshi Biosciences Co Ltd Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE524495T1 (de) * 2001-07-31 2011-09-15 Ono Pharmaceutical Co Pd-1-spezifische substanz
LT2439273T (lt) * 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
CN101589058A (zh) * 2006-10-20 2009-11-25 株式会社未来创药研究所 包含抗hb-egf抗体作为活性成分的癌症治疗剂
DK2170959T3 (da) * 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
DK2274008T3 (da) * 2008-03-27 2014-05-12 Zymogenetics Inc Sammensætninger og fremgangsmåder til hæmning af PDGFRBETA og VEGF-A
NO2344540T3 (fr) * 2008-10-02 2018-04-28
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
SG11201602283UA (en) * 2013-09-27 2016-04-28 Genentech Inc Anti-pdl1 antibody formulations
CN113402609B (zh) * 2013-12-20 2023-12-05 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
WO2015103139A1 (fr) * 2013-12-31 2015-07-09 Development Center For Biotechnology Anticorps anti-vegf et leur utilisation
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
TN2017000440A1 (en) * 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
EA201890790A1 (ru) * 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
US10766958B2 (en) * 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
WO2018053405A1 (fr) * 2016-09-19 2018-03-22 Celgene Corporation Procédés de traitement de troubles immunitaires à l'aide de protéines de liaison à pd-1

Also Published As

Publication number Publication date
KR20190141658A (ko) 2019-12-24
CN110678482A (zh) 2020-01-10
EP3601338A1 (fr) 2020-02-05
CL2019002605A1 (es) 2020-05-29
IL268884A (en) 2019-10-31
EP3601338A4 (fr) 2020-12-16
ECSP19076344A (es) 2019-10-31
CA3055984A1 (fr) 2018-10-04
CO2019010230A2 (es) 2020-01-17
JP2020512359A (ja) 2020-04-23
AU2018246252A1 (en) 2019-09-19
US20180289802A1 (en) 2018-10-11
BR112019018996A2 (pt) 2020-04-14
MX2019010999A (es) 2020-02-05
WO2018183459A1 (fr) 2018-10-04
EA201991912A1 (ru) 2020-03-10

Similar Documents

Publication Publication Date Title
SG11201907948TA (en) Formulations comprising pd-1 binding proteins and methods of making thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
CA3015496A1 (fr) Commande vocale d'un systeme de lecture multimedia
SG11201804915RA (en) Methods for treating huntington's disease
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201901126UA (en) Combination therapy for cancer
SG11201808708RA (en) Heterocyclic amides useful as protein modulators
SG11201901950TA (en) Methods of treating immune disorders using pd-1 binding proteins
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201907253VA (en) Proteins binding bcma, nkg2d and cd16
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity
SG11201908051RA (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
SG11201907646YA (en) Proteins binding her2, nkg2d and cd16
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201907638QA (en) Proteins binding cd33, nkg2d and cd16
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof